Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 1:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 336 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Parkinsons Disease (PD) Clear all
Suspended Phase 2 Interventional

Terazosin And Metabolic Energetics in Parkinson's Disease

NCT07464028
View directory record Official record
Conditions
Parkinson's Disease (PD)
Interventions
Terazosin 5 MG, Placebo
Drug
Lead sponsor
Nandakumar Narayanan
Other
Eligibility
50 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2028 – 2031
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 1, 2026, 1:55 PM EDT
Recruiting Phase 2 Interventional

Neural Mechanisms of Aerobic Exercise Benefits in PD With DBS

NCT07442747
View directory record Official record
Conditions
Parkinson's Disease, Deep Brain Stimulation
Interventions
Exercise
Behavioral
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 1, 2026, 1:55 PM EDT
Terminated Phase 3 Interventional Results available

NET-PD LS-1 Creatine in Parkinson's Disease

NCT00449865
View directory record Official record
Conditions
Parkinson's Disease
Interventions
creatine, placebo
Drug · Other
Lead sponsor
University of Rochester
Other
Eligibility
Not listed
Enrollment
1,741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
48
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2015 · Synced Oct 1, 2026, 1:55 PM EDT
Active, not recruiting No phase listed Observational

Genotypic Influences on Network Progression in Parkinson's Disease

NCT04228172
View directory record Official record
Conditions
Parkinson's Disease
Interventions
DNA/GeneticTesting, FDG PET scan, MRI scan, Clinical and neuropsychological assessments
Genetic · Radiation · Other
Lead sponsor
Northwell Health
Other
Eligibility
40 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 1, 2026, 1:55 PM EDT
Not listed Phase 4 Interventional

A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients

NCT01007630
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Rasagiline, Placebo
Drug
Lead sponsor
The Parkinson's Institute
Other
Eligibility
Up to 90 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Sunnyvale, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2013 · Synced Oct 1, 2026, 1:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cell Studies of Parkinson's Disease

NCT00076505
View directory record Official record
Conditions
Parkinson Disease
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 1, 2026, 1:55 PM EDT
Completed Phase 2 Interventional

Talampanel to Treat Parkinson's Disease

NCT00108667
View directory record Official record
Conditions
Parkinson Disease
Interventions
IV Levodopa, Talampanel
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 1, 2026, 1:55 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Characteristics of Parkinson s Disease Associated With the LRRK-2 Gene Mutation

NCT00467090
View directory record Official record
Conditions
Parkinson Disease
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 1, 2026, 1:55 PM EDT
Completed Phase 2 Interventional

A Study of NE3107 in Early Parkinson's

NCT06757010
View directory record Official record
Conditions
Parkinsons Disease (PD)
Interventions
NE3107, Placebo
Drug
Lead sponsor
BioVie Inc.
Industry
Eligibility
45 Years to 80 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Farmington Hills, Michigan • Amherst, New York • Morrisville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 1, 2026, 1:55 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

A Natural History Study of Patients With G2019S LRRK2 Parkinson's Disease

NCT05349019
View directory record Official record
Conditions
Patients With Parkinson's Disease (PD) Caused by the p.Gly2019Ser (G2019S) Pathogenic Mutation of the Leucine-Rich Repeat Kinase 2 (LRRK2) Gene
Interventions
Observational
Other
Lead sponsor
Escape Bio, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Oct 1, 2026, 1:55 PM EDT
Recruiting Not applicable Interventional

Understanding Motivation in Parkinson's Patients Through Neurophysiology

NCT05065151
View directory record Official record
Conditions
Parkinson Disease, Deep Brain Stimulation, Motivation
Interventions
Stimulation on, Stimulation off, Decision Making Task
Other · Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 1, 2026, 1:55 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients

NCT00479401
View directory record Official record
Conditions
Early Parkinson Disease (Early PD)
Interventions
Pramipexol Extended Release, Pramipexol Immediate Release, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
30 Years and older
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
16
States / cities
Gilbert, Arizona • Sun City, Arizona • La Jolla, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2014 · Synced Oct 1, 2026, 1:55 PM EDT
Not yet recruiting Not applicable Interventional

Behavioral Intervention for Lifestyle Physical Activity in Parkinson's Disease

NCT06603012
View directory record Official record
Conditions
Parkinson Disease (PD)
Interventions
GET Up PD, Stretching and Flexibility
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
50 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 1, 2026, 1:55 PM EDT
Completed Phase 1Phase 2 Interventional Results available

50 Hz Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Parkinson's Disease

NCT00977184
View directory record Official record
Conditions
Parkinson Disease
Interventions
50 HZ Repetitive TMS, Sham rTMS
Procedure
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
40 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 27, 2012 · Synced Oct 1, 2026, 1:55 PM EDT
Completed Phase 4 Interventional Results available

A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients

NCT00402233
View directory record Official record
Conditions
Parkinson Disease
Interventions
Pramipexole, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
31 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
39
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fountain Valley, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Oct 1, 2026, 1:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Cough According to Stimulus Type in PD

NCT02390089
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Capsaicin vapor, fog, Videofluoroscopic swallow evaluation, Nebulizer
Drug · Other · Radiation + 1 more
Lead sponsor
University of Florida
Other
Eligibility
50 Years to 80 Years
Enrollment
158 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 1, 2026, 1:55 PM EDT
Completed No phase listed Observational Results available

Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)

NCT03944785
View directory record Official record
Conditions
Idiopathic Parkinson Disease
Interventions
XADAGO (safinamide)
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
30
States / cities
Homewood, Alabama • Bakersfield, California • Laguna Hills, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Oct 1, 2026, 1:55 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort

NCT04477785
View directory record Official record
Conditions
Parkinson Disease
Interventions
Not listed
Lead sponsor
Michael J. Fox Foundation for Parkinson's Research
Other
Eligibility
30 Years and older
Enrollment
4,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2033
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 1, 2026, 1:55 PM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Mild Cognitive Impairment Community Screening and Early Intervention Via Stem Cell Therapy and Wearable Brain Computer Interface Device.

NCT07214974
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline, Alzheimer's Disease Dementia, Alzheimer's Disease Diagnosis, Alzheimer's Disease and Related Dementias, Parkinson's Disease, Parkinson's Disease (PD), Parkinson's Disease With Wearing-off Motor Fluctuations, Dementia (Diagnosis), Dementia MCI (Mild Cognitive Impairment)
Interventions
Structured wellness care, Wearable brain-computer interface devices, Stem Cell Therapy - Experimental, Control - Placebo Comparator
Behavioral · Device · Biological + 1 more
Lead sponsor
Noah Tech, Corp.
Industry
Eligibility
55 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Palisades Park, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 1, 2026, 1:55 PM EDT
Not listed No phase listed Observational

A Smartphone Application for Neurology and Telemedicine

NCT06245174
View directory record Official record
Conditions
Parkinson Disease(PD)
Interventions
Not listed
Lead sponsor
Altec Inc.
Industry
Eligibility
35 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Natick, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 1, 2026, 1:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Coping With Depression in Parkinson's Disease

NCT00464464
View directory record Official record
Conditions
Parkinson's Disease, Depression
Interventions
cognitive-behavioral therapy
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
35 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 5, 2014 · Synced Oct 1, 2026, 1:55 PM EDT
Completed Not applicable Interventional

Autologous Peripheral Nerve Grafts Into the Substantia Nigra of Subjects With PD Undergoing Deep Brain Stimulation

NCT01833364
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Implantation of the Peripheral Nerve Graft
Procedure
Lead sponsor
Craig van Horne, MD, PhD
Other
Eligibility
40 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Oct 1, 2026, 1:55 PM EDT
Completed Phase 3 Interventional

Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients

NCT00203164
View directory record Official record
Conditions
Parkinson's Disease
Interventions
rasagiline mesylate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
30 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
6
States / cities
Fresno, California • Chicago, Illinois • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2010 · Synced Oct 1, 2026, 1:55 PM EDT
Completed Phase 3 Interventional Results available

Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

NCT03750552
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypotension
Interventions
ampreloxetine, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
30 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
23
States / cities
Sun City, Arizona • Long Beach, California • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Oct 1, 2026, 1:55 PM EDT